C3N-02435
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 64.42436687
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.380
- MITOTIC_SPINDLE+0.380
- WNT_BETA_CATENIN_SIGNALING+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- E2F_TARGETS+0.250
- MYC_TARGETS_V2+0.200
- NOTCH_SIGNALING+0.200
- SPERMATOGENESIS+0.140
- APICAL_SURFACE+0.110
- HEDGEHOG_SIGNALING+0.080
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- ALLOGRAFT_REJECTION-0.480
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.470
- IL6_JAK_STAT3_SIGNALING-0.440
- CHOLESTEROL_HOMEOSTASIS-0.370
- COMPLEMENT-0.370
- OXIDATIVE_PHOSPHORYLATION-0.370
- UV_RESPONSE_UP-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013547 | — | cohortMD1 | 0.903 |
| 2 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.902 |
| 3 | SRR8613768 | — | E | 0.881 |
| 4 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.877 |
| 5 | SRR10899974 | — | — | 0.866 |
| 6 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.863 |
| 7 | 7478db87-0751-4771-941f-9fccdf01853d | — | — | 0.862 |
| 8 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.855 |
| 9 | SRR8392888 | — | cohortMD1 | 0.852 |
| 10 | 20100144.Her2HRpos | — | D | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.030 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |